Revolution Medicines
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Its last 5 Sell calls were actually followed by a +15% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +53.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -4,207.1% | Better than 1% |
| Net margin | -3,768.3% | Better than 2% |
| Return on equity | -58.1% | Better than 8% |
| Return on invested capital | -57.2% | Better than 5% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -23.0% | Better than 26% |
| 6-month return | 6.4% | Better than 67% |
| 12-month return (ex latest month) | 163.8% | Better than 98% |
| Distance below 52-week high | 28.1% | Better than 45% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 7.1x | Better than 91% |
| Debt to assets | 6.7% | Better than 75% |
| Interest coverage | -45.7x | Better than 7% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 95.7% | Better than 77% |
| Upside to average target | 66.4% | Better than 75% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 159.43
- Open
- 161.61
- Day range
- 160.22 - 169.51
- Avg price
- 163.11
- Volume
- 4.74M
- Turnover
- 773.48M
- Turnover ratei
- 2.39%
- Volume ratioi
- 1.74
- Amplitudei
- 5.83%
- 52-week rangei
- 71.15 - 224.31
Valuation
- P/Ei
- -27.09
- P/E (TTM)i
- -17.66
- P/Bi
- 14.52
- EPSi
- -5.95
- Book value / shi
- 11.10
- Net profit
- -1.29B
- Net assets
- 2.40B
Share structure
- Market cap
- 34.87B
- Float capi
- 31.94B
- Shares out
- 216.29M
- Float sharesi
- 198.15M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-02-13
28.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-16.21M net over the window
Short interest
- Shares short
- 13.08M
- % of floati
- 6.10%
- Days to coveri
- 7.76
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Revolution Medicines (RVMD)?
Revolution Medicines last traded at 161.20. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Revolution Medicines's market cap?
About 34.87B.
What is the P/E ratio of Revolution Medicines?
The trailing twelve-month P/E is -17.66. The Valuation tab shows it against the stock's own five-year range.
Does Revolution Medicines pay a dividend?
Revolution Medicines does not currently pay a regular dividend.
Is Revolution Medicines a buy according to analysts?
The consensus of 23 analysts is a Buy rating, with an average 12-month price target of 268.26, which implies 66.4% upside from the current price. This is not investment advice.
What is Revolution Medicines's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Revolution Medicines a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Revolution Medicines discussion 0 comments